Follicular Lymphoma Clinical Trial
Official title:
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma.
This study is a multicentric trial evaluating the efficacy of the RFM regimen in patients aged 18 to 75 years with relapsed/refractory follicular non-Hodgkin's lymphoma (NHL).
Follicular non Hodgkin's lymphoma's (FL), as defined by the Revised European American
Lymphoma Classification (REAL) Classification, are usually characterized by a slowly
progressive clinical course, a transient control by standard chemotherapeutic regimen and a
pattern of repeated relapses until ultimately progressive and fatal disease.
Standard first line treatment for advanced FL consists of alkylating-based (CVP) or
anthracycline containing regimen in association to interferon alpha (CHVP+IFN) chemotherapy.
Others approaches have been developed mostly as secondary therapy including purine analogs
alone or in combination with alkylators or mitoxantrone, high dose therapy with autologous
peripheral stem cell transplantation and, more recently, treatment with the unconjugated
chimeric anti-CD20 antibody (rituximab) to target the CD20 antigen highly expressed on
follicular lymphoma cells. None of these strategies does appear to give a definitive survival
advantage. Thus, in patients with FL, the design of novel combination programs is a major
challenge.
Combination of fludarabine and mitoxantrone in low grade, predominantly Follicular NHL:
results of phase II studies in relapsed or refractory patients Fludarabine is expected to
potentiate other agents through inhibition of DNA polymerase alpha and DNA ligase and its
consequent interference with the DNA repair process. The addition of mitoxantrone increases
the cytotoxic effect of fludarabine in vitro. McLaughlin et al developed a combination of
fludarabine, mitoxantrone and dexamethasone (FND), which was very effective in 51 patients
with recurrent low-grade lymphoma (including 65% FL), with an overall response rate of 94%
(47% complete response (CR) rate. The median duration of response in this phase II study was
21 months for CR patients but only 9 months for partial responders (PR) patients. The median
survival and failure-free survival times from the time of entry onto the FND study were 34
and 14 months, respectively. Most major responses were evident after two to four courses of
chemotherapy. The need for continuation of therapy beyond attainment of remission is
suggested by early relapses among patients who had early discontinuation of therapy. The
predominant toxic effects were myelosuppression and infections: neutropenia < 500/µl in 20 %
of courses, thrombopenia < 50000/µl in 8 % of courses and infections in 12 % of courses.
Non-hematological toxicity was modest.
FND appears to be comparable to, and less toxic than the combination of etoposide,
methylprednisolone, cytarabine, and cisplatin (ESHAP), one of the most effective regimens
available for patients with relapsed indolent lymphoma. Others studies have confirmed the
significant efficacy and moderate toxicity profile of this combination as salvage therapy in
low grade, predominantly follicular lymphoma.
Moreover, the omission of corticosteroids reduces the risk of opportunistic infections, while
the activity of the combination against indolent lymphoma is maintained.
Preliminary data from rituximab studies alone or in combination with chemotherapy in relapsed
or refractory low grade NHL In vitro, rituximab mediates complement dependent cytotoxicity
(CDC), antibody dependent cellular cytotoxicity (ADCC) and apoptosis. However, the mechanism
of in vivo anti-lymphoma effect remains largely unknown. Rituximab received approval for
recurrent follicular lymphoma based on response rates of about 50% including 6% complete
responses and duration of responses, which compare favorably to that of all other single
agents including fludarabine and 2-CdA (15-19). Median time to progression for responders is
around 13 months. Toxicity of rituximab is low and easily manageable. An 8 doses schedule did
not show to confer a significant advantage in term of response rate and duration of response
over the four doses schedule.
Rituximab has been shown to sensitize drug-resistant lymphoma cell lines to killing by
cytotoxic drugs including fludarabine.
Thus, we may hypothesize that the combination of rituximab, fludarabine and mitoxantrone
might lead to synergistic / additive induction of apoptosis through different pathways in
lymphoma B-cells which maintain an indolent growth pattern.
This approach may provide a means to achieve longer progression free survival in relapsed or
refractory patients with FL.
We opted for a four induction cycles of rituximab, fludarabine and mitoxantrone since:
1. Four cycles of a combination of fludarabine and mitoxantrone are generally sufficient to
assess response,
2. the 4 doses schedule of rituximab which has been the most studied is efficient 3) The
omission of dexamethasone does not appear to impair ORR and Duration Response (DR) of a
combination of fludarabine and novantrone . Recycling will start on day 28.
Subsequently responding patients according the International criteria Working group will have
2 more cycle of a combination of fludarabine and mitoxantrone but no rituximab.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03078855 -
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT03245021 -
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
|
Phase 1 | |
Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02213263 -
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
|
Phase 3 | |
Completed |
NCT01691898 -
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Terminated |
NCT03585725 -
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
|
Early Phase 1 | |
Terminated |
NCT00772668 -
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
|
N/A | |
Recruiting |
NCT02892695 -
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Terminated |
NCT02204982 -
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
|
Phase 3 | |
Terminated |
NCT00850499 -
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
|
Phase 2 | |
Completed |
NCT02536664 -
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
|
||
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Terminated |
NCT00136591 -
A Phase 2 Study of Velcadeā¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06068881 -
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
|
Phase 2 | |
Completed |
NCT04034056 -
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
|